PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29134664-12	2018	The combination of ruxolitinib and azacytidine was well-tolerated with an ICP MDS/MPN-response rate of 57% in patients with MDS/MPNs.	Azacitidine	35-46	serine protease 27	Homo sapiens	82-85	
20664061-7	2010	Azacitidine gives encouraging results in Ph-negative MPN having progressed to AML or MDS, but response duration is short, and consolidation treatments have to be evaluated.	Azacitidine	0-11	serine protease 27	Homo sapiens	53-56